Xenon Pharmaceuticals Inc. (XENE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XENE Revenue Growth
Revenue Breakdown (FY 2022)
XENE's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
XENE Revenue Analysis (2014–2025)
As of May 8, 2026, Xenon Pharmaceuticals Inc. (XENE) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, XENE's 5-year compound annual growth rate (CAGR) stands at -25.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $32.2 million in 2020.
Revenue diversification analysis shows XENE's business is primarily driven by License and Service (100%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), PTCT (-53.3% YoY), and ARVN (-0.3% YoY), XENE has underperformed the peer group in terms of revenue growth. Compare XENE vs ACAD →
XENE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XENECurrent | $0 | -100.0% | -25.3% | -4974.3% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 OVID | $7M | +1181.3% | -10.5% | -585.2% |
XENE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.5M | - | $5.0M | 66.1% | $-373,070,000 | -4974.3% |
| 2024 | $0 | - | $-2,560,000 | - | $-279,298,000 | - |
| 2023 | $0 | -100.0% | $-167,512,000 | - | $-214,054,000 | - |
| 2022 | $9.4M | -48.8% | $9.4M | 100.0% | $-129,143,000 | -1368.9% |
| 2021 | $18.4M | -42.7% | $18.4M | 100.0% | $-78,993,000 | -428.4% |
| 2020 | $32.2M | +371.0% | $32.2M | 100.0% | $-31,301,000 | -97.3% |
| 2019 | $6.8M | - | $6.8M | 100.0% | $-42,819,000 | -627.0% |
| 2018 | $0 | -100.0% | $-6,000,000 | - | $-38,016,000 | - |
| 2017 | $311K | -82.8% | $-25,262,000 | -8122.8% | $-32,575,000 | -10474.3% |
| 2016 | $1.8M | -88.4% | $689K | 38.2% | $-24,817,000 | -1376.4% |
See XENE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XENE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XENE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXENE — Frequently Asked Questions
Quick answers to the most common questions about buying XENE stock.
Is XENE's revenue growth accelerating or slowing?
XENE revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -25.3%. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is XENE's long-term revenue growth rate?
Xenon Pharmaceuticals Inc.'s 5-year revenue CAGR of -25.3% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is XENE's revenue distributed by segment?
XENE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.